Fri Sep 26 06:50:00 UTC 2025: **Summary:**
President Trump’s imposition of 100% tariffs on branded drugs is causing significant concern for Indian pharmaceutical companies. Stocks like Sun Pharma, Cipla, and Dr. Reddy’s have been affected due to their substantial revenue exposure in the US market. The potential expansion of tariffs to complex generics intensifies the worry. While companies with US manufacturing plants might experience some relief, the overall future of Indian pharma exports remains uncertain.
**News Article:**
**Trump’s Drug Tariffs Slam Indian Pharma Stocks**
**New Delhi:** Indian pharmaceutical giants are reeling from President Trump’s latest trade offensive: a 100% tariff on branded drugs imported from India. Shares of major players like Sun Pharma, Cipla, and Dr. Reddy’s Laboratories took a hit on the news, as analysts warn of potential earnings declines.
The tariffs, aimed at lowering drug prices in the US, pose a significant threat to Indian pharma companies that rely heavily on the US market for revenue. The situation could worsen if the tariffs are extended to include complex generic drugs, where Indian firms hold a substantial market share.
“This is a serious blow,” said a market analyst. “Companies with significant US revenue exposure are looking at a potentially painful period.”
While some Indian firms with existing manufacturing plants in the US might be partially insulated, the overall impact on the Indian pharmaceutical export sector remains uncertain. The industry is now bracing for further developments as the trade dispute unfolds.
First Piper 